IKZF1 status as a prognostic feature in BCR-ABL1–positive childhood ALL

Author:

van der Veer Arian1,Zaliova Marketa23,Mottadelli Federica4,De Lorenzo Paola45,te Kronnie Gertruuy6,Harrison Christine J.7,Cavé Hélène8,Trka Jan3,Saha Vaskar9,Schrappe Martin2,Pieters Rob110,Biondi Andrea4,Valsecchi Maria Grazia5,Stanulla Martin2,den Boer Monique L.110,Cazzaniga Giovanni4

Affiliation:

1. Department of Pediatric Oncology, Erasmus University Medical Center-Sophia Children’s Hospital, Rotterdam, The Netherlands;

2. Department of Pediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany;

3. Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, 2nd Faculty of Medicine, Childhood Leukemia Investigation Prague, Prague, Czech Republic;

4. Clinica Pediatrica, Centro Ricerca Tettamanti, University of Milano-Bicocca, Mona, Italy;

5. European Study for Philadelphia–Acute Lymphoblastic Leukemia Trial Data Center, Department of Health Sciences, University of Milano-Bicocca, Monza, Italy;

6. Department of Women's and Children's Health, University of Padova, Padova, Italy;

7. Leukemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;

8. Department of Genetics, Assitance Publique Hôpitaux de Paris, Hôspital Robert Debré, University Paris Diderot, Paris, France;

9. Children’s Cancer Group, Manchester Academic Health Science Center, University of Manchester, Manchester, United Kingdom; and

10. Dutch Childhood Oncology Group, The Hague, The Netherlands

Abstract

Key Points IKZF1 deletions are predictive of an unfavorable outcome in childhood BCR-ABL1–positive ALL. Good-risk BCR-ABL1–positive patients with wild-type IKZF1 have good outcomes when treated with imatinib.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 136 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3